Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods of treating malignant lymphoproliferative disorders

A technology for lymphoid hyperplasia and malignancy, which is used in pharmaceutical formulations, organic active ingredients, medical preparations containing active ingredients, etc.

Pending Publication Date: 2021-02-09
ACTUATE THERAPEUTICS INC
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although 60% of patients enjoy long-term disease-free survival, a proportion of biologically unfavorable patients with chemotherapy-refractory disease has less favorable outcomes

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods of treating malignant lymphoproliferative disorders
  • Methods of treating malignant lymphoproliferative disorders
  • Methods of treating malignant lymphoproliferative disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0122] Example 1 - Viability and Proliferation Assay (MTS Assay)

[0123] After treating cells with different concentrations of 9-ING-41, Promega CellTiter The AQueous One Solution Cell Proliferation Assay (MTS) measures cell viability at day 3 and proliferation over the course of 7 days according to the manufacturer's instructions. At the end of the treatment, add 20 µL of reagent per well in the 96-well plate and incubate at 37 °C for 2-4 h. Absorbance at 490 nm (A490) was measured using a Powerwave XS plate reader (Biotek).

[0124] All lymphoma cell lines used in this study expressed active GSK-3β. SUDHL-4, KPUM-UH1, Karpas 422, or TMD8 lymphoma cells were plated and cell numbers were measured on days 1, 3, 5, and 7 using the MTS assay. See Figure 1. After 1 μM 9-ING-41 treatment, the cell viability on day 3 ( Figure 1A ) was reduced by 40-70% (p Figures 1B-1E ), the proliferation on day 7 was less than 30% relative to the control (p<0.05). Cell viability of lymph...

Embodiment 3-W

[0130] Example 3 - Western blot analysis

[0131]c-MYC levels in KPUM-UH1 cells were analyzed by Western blot for 9-ING-41 alone and 9-ING-41 in combination with venetoclax or BAY-1143572. Approximately 10 million cells were spun at 200 rcf for 5 min and rinsed once with PBS before lysing in 50 μl Millipore Milliplex MAP lysis buffer supplemented with protease and phosphatase inhibitors (Roche). Each well was loaded with denatured protein in 4X sample buffer supplemented with β-mercaptoethanol (Bio-Rad). Bio-Rad stain-free Criterion 4-20% precast gels were used. After running the gel at 140 volts for 90 min, the stain-free technique was activated using a Bio-Rad gel imager to visualize the level of total protein loaded in the gel. The protein was then transferred to the membrane using a nitrocellulose turbo-transfer kit and system (Bio-Rad), and the membrane was blocked using 5% w / v dry milk in Tris-buffered saline-0.1% Tween 20 (TBS-T)1 Hour. Membranes were then incubat...

Embodiment 4

[0132] Example 4-Luminex analysis

[0133] NF-κB associated with 1 μM 9-ING-41 treatment for 48 hours compared to untreated controls was determined using the FLEXMAP 3D instrument according to the manufacturer's instructions [MILLIPLEXMAP NF-κB Signal Transduction Magnetic Bead Kit 6-plex Kit, EMD Millipore, Analytes: c-MYC, FADD (Ser194), IκBα (Ser32), IKKα / β (Ser177 / Ser181), NF-κB (Ser536), TNFR1], DNA damage [MILLIPLEX MAP DNA damage / Genotoxic Magnetic Bead Set, EMD Millipore, Analytes: ATR(Total), Chk1(Ser345), Chk2(Thr68), H2A.X(Ser139), MDM2(Total), p21(Total), p53(Ser15)] and Apoptotic Pathway [Bio-plex pro RBM Apoptosis Group 2 and 3, Bio-Rad, Analytes: Bad, Bax / Bcl-2dimer, Bcl-xL, Bim, Mcl-1, Active Caspase 3, Bcl-xL / Bak dimer, Mcl-1 / Bak dimer, survivin] signaling changes. Cells were lysed in MILLIPLEX MAP Lysis Buffer supplemented with Protease Inhibitor Cocktail (Sigma) and Phosphatase Inhibitor Cocktails 2 and 3 (Sigma), and after BCA protein determination, 1...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Methods of treating malignant ly mphopr oli ferati ve disorders in a patient, comprising administering an effective amount of a GSK-3beta inhibitor, for example 9-ING-41, are provided. Also provided are methods for treating malignant lymphoprohferative disorders comprising administering a (GSK-3beta inhibitor, for example 9-ING-41, in combination with a second or multiple therapeutic agents.

Description

[0001] Cross References to Related Applications [0002] This application claims the benefit of priority to U.S. Provisional Application No. 62 / 680,739, filed June 5, 2018, the entire contents of which are incorporated herein by reference. technical field [0003] The present disclosure relates to the use of GSK-3β inhibitors including 3-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-[1,3]dioxo[4,5- f] indol-7-yl) pyrrole-2,5-dione) method for treating malignant lymphoproliferative diseases. Background technique [0004] Malignant lymphoproliferative disorders are a group of diseases characterized by abnormal proliferation of lymphocytes. The two general types of malignant lymphoproliferative disorders are malignant B-cell lymphoproliferative disorders and malignant T-cell lymphoproliferative disorders. [0005] Malignant B-cell lymphoproliferative disorders include diffuse large B-cell lymphoma, acute lymphoblastic leukemia, lymphoid blast phase Chronic Myeloid Leukemia, chroni...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61P35/00A61P35/02A61P43/00C07D471/04
CPCA61K31/404A61K45/06A61P35/02A61P35/00A61P43/00A61K2300/00A61K31/407A61K31/5517A61K31/433A61K31/635A61K31/5377A61K31/52A61K31/53A61K31/4025A61K31/496
Inventor 弗朗西斯·贾尔斯安德鲁·马扎尔
Owner ACTUATE THERAPEUTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com